22 MARKET NEWS

Changes in the UK market o ItIa6ae-Poaienc Rorer bas launched once-dally .....,..., 'Nil ..... XL' onto the UK market. This is the first once-daily nifedipine to reach this market; Bayer's sustained-release nifedipine, 'Adalat Retard', has a twice-daily regimen. The calcium antagonist is approved for the treatment of hypertension.

'Nifensar XL' is licensed from Elan, and utilises Elan's INDAS (insoluble drug absorption system) controlled drug release technology.

RhOne-Poulenc Rorer have already launched the product in Ireland, which acted as rapporteur to the European Community's Committee for Proprietary Medicinal Products (CPMP). The CPMP recommended the product for approval, and it has been approved in Belgium, Denmark, The Netherlands, Germany, and Greece, among others, where it will be marketed by Farmitalia Carlo Erba. o ' .......... SR' Iiceased for endometriosis. The indications for Lederle's leuprorelin depot injection ('Prostap SR') have been extended to include the treatment of endometriosis. The product acts as a LHRH agonist, and was introduced into the UK for the treatment of prostatic cancer last year.

1 feb 1992lNPHARMAe

'l'6

ISSN 0156-2703/92/0201-0022/0$01.00/0 CAllis ....... iUIIoIlGI lid